2023
Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database
Yumeen S, Mirza F, Mirza H, Zogg C, Leventhal J, Cohen J. Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database. Journal Of The American Academy Of Dermatology 2023, 89: 843-846. PMID: 37343827, DOI: 10.1016/j.jaad.2023.05.090.Peer-Reviewed Original ResearchHistopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanoma
Belzer A, Becerra C, Clune J, Malik M, Leventhal J, Cowper S, Johnson R. Histopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanoma. Journal Of Cutaneous Pathology 2023, 50: 471-474. PMID: 36645720, DOI: 10.1111/cup.14376.Peer-Reviewed Original Research
2021
Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma
Pach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatology 2021, 157: 468-469. PMID: 33688919, DOI: 10.1001/jamadermatol.2021.0058.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, ImmunologicalFemaleHumansMelanomaNecrosisNivolumabSkin NeoplasmsSubcutaneous Fat
2020
Association between halo nevi and melanoma in adults: A multicenter retrospective case series
Haynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling TM. Association between halo nevi and melanoma in adults: A multicenter retrospective case series. Journal Of The American Academy Of Dermatology 2020, 84: 1164-1166. PMID: 32822787, DOI: 10.1016/j.jaad.2020.08.056.Peer-Reviewed Original ResearchEpidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical course
Mirza FN, Yumeen S, Zogg CK, Mirza HN, Leventhal JS. Epidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical course. Journal Of The American Academy Of Dermatology 2020, 83: 1827-1830. PMID: 32446830, PMCID: PMC7669598, DOI: 10.1016/j.jaad.2020.05.086.Peer-Reviewed Original ResearchCutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.
Tattersall IW, Leventhal JS. Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist. The Yale Journal Of Biology And Medicine 2020, 93: 123-132. PMID: 32226342, PMCID: PMC7087048.Peer-Reviewed Original ResearchMeSH KeywordsDermatologyDrug EruptionsHumansImmune Checkpoint InhibitorsMolecular Targeted TherapySkin NeoplasmsConceptsCutaneous irAEsImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitionImmune checkpoint inhibitorsPotential adverse eventsPotential prognostic significanceNumber of cancersOnly carcinogenesisCheckpoint inhibitorsAdverse eventsCutaneous toxicityInhibitor therapyCheckpoint inhibitionPrognostic significanceCommon siteClinical characterizationPrimary dermatosesIrAEsTherapeutic promiseTreatment of diseasesTherapyCancerTreatmentDermatologistsNear total body vitiligo secondary to immunotherapy for metastatic melanoma
Olamiju B, Leventhal J. Near total body vitiligo secondary to immunotherapy for metastatic melanoma. British Journal Of Dermatology 2020, 183: e2-e2. PMID: 32147813, DOI: 10.1111/bjd.18944.Peer-Reviewed Case Reports and Technical Notes
2019
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original ResearchConceptsPD-1 inhibitorsB cell contentB-cell depletionAnti-tumor activityB cellsMuMT miceCell depletionAnti-PD-1 inhibitorsAnti-PD-1 responseB-cell depleting drugsTumor-infiltrating B cellsImpaired B-cell functionT cell-dependent tumor rejectionPD-1 inhibitionMC38 colon cancerB cell functionAnti-tumor effectsB-cell malignanciesMurine cancer modelsCell contentOverall survivalTumor rejectionCD20 antibodyAutoimmune disordersTumor shrinkage
2018
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug EruptionsExanthemaFemaleHumansIpilimumabLichenoid EruptionsMaleMiddle AgedNivolumabRetrospective StudiesSkin NeoplasmsStevens-Johnson SyndromeWithholding TreatmentConceptsInflammatory eruptionsCheckpoint inhibitorsTherapeutic responseImmune checkpoint inhibitor therapySingle tertiary care centerSingle-institution retrospective analysisYale-New Haven HospitalCheckpoint inhibitor therapyTertiary care centerMinority of patientsInpatient dermatology serviceDegree of severityMost rashesInhibitor therapyRetrospective studyTopical treatmentEarly recognitionMedical recordsCare centerInflammatory reactionRetrospective analysisDermatology servicesImmunotherapyMean latencyGrade 2Hypertrophic Lichen Planus and Well-Differentiated Squamous Cell Carcinoma
Totonchy MB, Leventhal JS, Ko CJ, Leffell DJ. Hypertrophic Lichen Planus and Well-Differentiated Squamous Cell Carcinoma. Dermatologic Surgery 2018, 44: 1466-1470. PMID: 29360655, DOI: 10.1097/dss.0000000000001465.Peer-Reviewed Original ResearchViolaceous plaques and papulonodules on the umbilicus.
Leventhal JS, Yin E, Imaeda S. Violaceous plaques and papulonodules on the umbilicus. Cutis 2018, 101: e11-e13. PMID: 29718029.Peer-Reviewed Case Reports and Technical Notes
2016
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1 therapyCutaneous adverse effectsPD-L1 therapyCell death 1Concurrent medicationsDeath-1Adverse effectsClinical morphologyAnti-PD-1/PD-L1 treatmentAnti-programmed cell death ligand-1 (PD-L1) immunotherapiesAnti-programmed cell death 1Non-small cell lung cancerDeath ligand 1 (PD-L1) immunotherapyPD-L1 antibody therapyCell death ligand 1Yale-New Haven HospitalMucocutaneous adverse effectsPD-L1 treatmentTreatment of rashTertiary care hospitalDeath ligand 1Lichenoid drug eruptionCell lung cancerSkin biopsy specimensRecent US FoodSkin manifestations of endocrine and neuroendocrine tumors
Leventhal JS, Braverman IM. Skin manifestations of endocrine and neuroendocrine tumors. Seminars In Oncology 2016, 43: 335-340. PMID: 27178685, DOI: 10.1053/j.seminoncol.2016.02.022.Peer-Reviewed Original Research
2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. Journal Of The American Academy Of Dermatology 2015, 73: 645-654. PMID: 26259990, DOI: 10.1016/j.jaad.2015.06.060.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAminoquinolinesCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImiquimodInjections, IntralesionalInterleukin-2MaleMelanomaNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRetinoidsRetrospective StudiesRisk AssessmentSkin NeoplasmsTreatment OutcomeConceptsIntralesional IL-2Cutaneous melanoma metastasesCutaneous metastatic melanomaIL-2Topical imiquimodMetastatic melanomaMelanoma metastasesCase seriesUS National Comprehensive Cancer Network guidelinesCommon treatment-related adverse eventsResponse rateNational Comprehensive Cancer Network guidelinesTreatment-related adverse eventsComplete response rateRetrospective case seriesPromising therapeutic optionLocal response rateAdverse eventsRetrospective reviewSurgical excisionNetwork guidelinesTherapeutic optionsCombination therapyBiopsy specimensRetinoid cream